CFTR and cystic fibrosis: These findings strongly support the utility of CRISPR/Cas9‐edited epithelial cell lines in testing the efficacy of companion therapies required to boost the response of rare CF‐causing mutant proteins to CFTR modulators previously approved for the major mutant: ΔF508‐CFTR.